JP2022500423A5 - - Google Patents

Info

Publication number
JP2022500423A5
JP2022500423A5 JP2021513996A JP2021513996A JP2022500423A5 JP 2022500423 A5 JP2022500423 A5 JP 2022500423A5 JP 2021513996 A JP2021513996 A JP 2021513996A JP 2021513996 A JP2021513996 A JP 2021513996A JP 2022500423 A5 JP2022500423 A5 JP 2022500423A5
Authority
JP
Japan
Prior art keywords
combination
pharmaceutical compositions
compositions according
therapeutic agent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500423A (ja
JP7441213B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001035 external-priority patent/WO2020053664A1/en
Publication of JP2022500423A publication Critical patent/JP2022500423A/ja
Publication of JP2022500423A5 publication Critical patent/JP2022500423A5/ja
Application granted granted Critical
Publication of JP7441213B2 publication Critical patent/JP7441213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513996A 2018-09-13 2019-09-13 エストロゲン受容体陽性乳癌の治療のための併用療法 Active JP7441213B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730837P 2018-09-13 2018-09-13
US62/730,837 2018-09-13
PCT/IB2019/001035 WO2020053664A1 (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of estrogen-receptor positive breast cancer

Publications (3)

Publication Number Publication Date
JP2022500423A JP2022500423A (ja) 2022-01-04
JP2022500423A5 true JP2022500423A5 (cg-RX-API-DMAC7.html) 2022-09-22
JP7441213B2 JP7441213B2 (ja) 2024-02-29

Family

ID=69777646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513996A Active JP7441213B2 (ja) 2018-09-13 2019-09-13 エストロゲン受容体陽性乳癌の治療のための併用療法

Country Status (8)

Country Link
US (1) US20220047563A1 (cg-RX-API-DMAC7.html)
EP (1) EP3849550B1 (cg-RX-API-DMAC7.html)
JP (1) JP7441213B2 (cg-RX-API-DMAC7.html)
CN (1) CN112912078B (cg-RX-API-DMAC7.html)
CA (1) CA3110788A1 (cg-RX-API-DMAC7.html)
ES (1) ES2993363T3 (cg-RX-API-DMAC7.html)
TW (1) TWI841598B (cg-RX-API-DMAC7.html)
WO (1) WO2020053664A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
WO2014128655A1 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
KR102307566B1 (ko) * 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
BR122019007990B1 (pt) * 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
WO2016203335A1 (en) * 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017015027A1 (en) * 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
US20180153867A1 (en) * 2016-12-06 2018-06-07 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent
US20180153868A1 (en) * 2016-12-06 2018-06-07 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
EP3758753A1 (en) * 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor

Similar Documents

Publication Publication Date Title
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
JP2024507938A5 (cg-RX-API-DMAC7.html)
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
JP2014512356A5 (cg-RX-API-DMAC7.html)
WO2016133903A3 (en) Combination therapy for cancer treatment
JP2016528162A (ja) がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
JP2016528162A5 (cg-RX-API-DMAC7.html)
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
JP2019526595A5 (cg-RX-API-DMAC7.html)
JP2024516795A5 (cg-RX-API-DMAC7.html)
JP2024516363A5 (cg-RX-API-DMAC7.html)
MX2013008673A (es) Derivados del tipo del azaindazol o diazaindazol como medicamento.
JP2015528501A5 (cg-RX-API-DMAC7.html)
JP2020523354A5 (cg-RX-API-DMAC7.html)
RU2015155283A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
TN2012000493A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
JP2009506054A5 (cg-RX-API-DMAC7.html)
JP2006500346A5 (cg-RX-API-DMAC7.html)
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
JP2014512355A5 (cg-RX-API-DMAC7.html)
RU2017128616A (ru) Комбинированное лекарственное средство
JP2013511526A5 (cg-RX-API-DMAC7.html)
JP2017507151A5 (cg-RX-API-DMAC7.html)
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
JP2022500431A5 (cg-RX-API-DMAC7.html)